Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy ...

Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind ...

In line with the "We the UAE 2031" Vision, the summit focused on improving quality of life and advancing specialized care for ...

The battle to drastically reduce, if not totally eradicate, dengue cases must involve yearlong efforts. It cannot be a ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

Takeda’s Board of Directors has unanimously appointed Julie Kim, currently the president of Takeda’s U.S. Business Unit, as ...

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co (TKPHF – Research Report).

With a growing footprint in health-care analytics and digital transformation, global consulting powerhouse ZS Associates is ramping up its presence in Jamaica, betting on the island’s talent pool to ...

Zydus Takeda Healthcare Private Limited (ZTHPL), a joint venture company set up by Zydus Lifesciences Limited and Takeda ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...